BFM
KPRX icon

Boothbay Fund Management’s Kiora Pharmaceuticals KPRX Stock Holding History

Boothbay Fund Management’s Portfolio KPRX Stock Details KPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,298
Closed -$40.1K – 2339
2022
Q4 		$40.1K Buy
+1,298
New +$59.8K ﹤0.01% 1891

Other funds holding KPRX

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Boothbay Fund Management's KPRX Position: Q1 2023 in Review

Boothbay Fund Management sold out of Kiora Pharmaceuticals (KPRX) in Q1 2023, closing a stake of 1,298 shares — an estimated $40.1K sold.

Boothbay Fund Management first reported a position in KPRX in Q4 2022 and held it in 1 quarter. The position peaked at $40.1K in Q4 2022. 14 funds tracked by Wall St. Rank hold KPRX as of Q1 2023.

  • Boothbay Fund Management reported no remaining Kiora Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Boothbay Fund Management sold 1,298 Kiora Pharmaceuticals shares in Q1 2023, an estimated $40.1K.
  • Boothbay Fund Management first reported a position in Kiora Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Boothbay Fund Management's Kiora Pharmaceuticals position peaked at $40.1K in Q4 2022.
  • 14 funds tracked by Wall St. Rank held Kiora Pharmaceuticals as of Q1 2023.

Based on Boothbay Fund Management's 13F filing for Q1 2023, filed 15 May 2023.